Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics

Bibliography

• Estanqueiro M, Amaral MH, Conceicao J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: The state of the art. Colloids Surf B Biointerfaces 2015;126:631–48
   PubMed Web of Science ®Google Scholar
• Schneider P, Van Dreden P, Rousseau A, et al. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol 2010;148:582–92
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. In vitro assays for monitoring nanoparticle interaction with components of the immune system. In: Dobrovolskaia MA, McNeil SE, editors. Handbook of immunological properties of engineered nanomaterials. World Scientific publishing Co. Pte. Ltd; Singapore: 2013. p. 582–639
   Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–803
   PubMed Web of Science ®Google Scholar
• de Leon MC, Bolla S, Greene B, et al. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep 2013;5:70–1
   PubMedGoogle Scholar
• Steinmetz T, Schaadt M, Gahl R, et al. Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor. J Biol Response Mod 1988;7:417–23
   PubMedGoogle Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010;16:6139–49
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther 2015; In press
   PubMed Web of Science ®Google Scholar
• Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010;123:1183–9
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967–77
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 2008;9:1317–23
   PubMed Web of Science ®Google Scholar
• Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 2009;5:8–20
   PubMed Web of Science ®Google Scholar
• Shegokar R, Al Shaal L, Mishra PR. SiRNA delivery: challenges and role of carrier systems. Pharmazie 2011;66:313–18
   PubMed Web of Science ®Google Scholar
• Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J 2009;11:639–52
   PubMed Web of Science ®Google Scholar
• Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) 2013;6:85–107
   PubMedGoogle Scholar
• Zhang Y, Kim WY, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013;34:3447–58
   PubMed Web of Science ®Google Scholar
• Vasilyeva SV, Silnikov VN, Shatskaya NV, et al. SiO(2) nanoparticles as platform for delivery of nucleoside triphosphate analogues into cells. Bioorg Med Chem 2013;21:703–11
   PubMed Web of Science ®Google Scholar
• Giacalone G, Bochot A, Fattal E, Hillaireau H. Drug-induced nanocarrier assembly as a strategy for the cellular delivery of nucleotides and nucleotide analogues. Biomacromolecules 2013;14:737–42
   PubMed Web of Science ®Google Scholar
• Zhang DY, Shen XZ, Wang JY, et al. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World J Gastroenterol 2008;14:3554–62
   PubMed Web of Science ®Google Scholar
• Raveendran S, Poulose AC, Yoshida Y, et al. Bacterial exopolysaccharide based nanoparticles for sustained drug delivery, cancer chemotherapy and bioimaging. Carbohydr Polym 2013;91:22–32
   PubMed Web of Science ®Google Scholar
• Simeonova M, Velichkova R, Ivanova G, et al. Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. Int J Pharm 2003;263:133–40
   PubMed Web of Science ®Google Scholar
• Phillips NC, Skamene E, Tsoukas C. Liposomal encapsulation of 3’-azido-3’-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression. J Acquir Immune Defic Syndr 1991;4:959–66
   PubMed Web of Science ®Google Scholar
• Phillips NC, Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992;79:1137–43
   PubMed Web of Science ®Google Scholar
• Kohli E, Han HY, Zeman AD, Vinogradov SV. Formulations of biodegradable Nanogel carriers with 5’-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J Control Release 2007;121:19–27
   PubMed Web of Science ®Google Scholar
• Szulc A, Appelhans D, Voit B, et al. Studying complexes between PPI dendrimers and Mant-ATP. J Fluoresc 2013;23:349–56
   PubMed Web of Science ®Google Scholar
• Cosco D, Rocco F, Ceruti M, et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int J Nanomedicine 2012;7:2535–46
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res 2012;36:1283–9
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen H, Wang Y, et al. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics. Int J Nanomedicine 2014;9:695–710
   PubMed Web of Science ®Google Scholar
• Klimuk SK, Semple SC, Nahirney PN, et al. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. J Pharmacol Exp Ther 2000;292:480–8
   PubMed Web of Science ®Google Scholar
• Gokhale PC, Zhang C, Newsome JT, et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 2002;8:3611–21
   PubMed Web of Science ®Google Scholar
• Drzewinska J, Appelhans D, Voit B, et al. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Biochem Biophys Res Commun 2012;427:197–201
   PubMed Web of Science ®Google Scholar
• Movassaghian S, Moghimi HR, Shirazi FH, et al. Efficient down-regulation of PKC-alpha gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes. Int J Pharm 2013;441:82–91
   PubMedGoogle Scholar
• Nourazarian AR, Najar AG, Farajnia S, et al. Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Dendrimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev 2012;13:4751–6
   PubMed Web of Science ®Google Scholar
• Nourazarian AR, Pashaei-Asl R, Omidi Y, Najar AG. c-Src antisense complexed with PAMAM dendrimers decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev 2012;13:2235–40
   PubMed Web of Science ®Google Scholar
• Prakash TP, Lima WF, Murray HM, et al. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. ACS Chem Biol 2013;8:1402–6
   PubMed Web of Science ®Google Scholar
• Bahal R, McNeer NA, Ly DH, et al. Nanoparticle for delivery of antisense gammaPNA oligomers targeting CCR5. Artif DNA PNA XNA 2013;4:49–57
   PubMedGoogle Scholar
• Inoue S, Ding H, Portilla-Arias J, et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res 2011;71:1454–64
   PubMed Web of Science ®Google Scholar
• Inoue S, Patil R, Portilla-Arias J, et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One 2012;7:e31070
   PubMed Web of Science ®Google Scholar
• Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 2013;34:7939–49
   PubMed Web of Science ®Google Scholar
• Wang M, Wu B, Lu P, et al. Pluronic-PEI copolymers enhance exon-skipping of 2’-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice. Gene Ther 2014;21:52–9
   PubMed Web of Science ®Google Scholar
• Huschka R, Barhoumi A, Liu Q, et al. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano 2012;6:7681–91
   PubMed Web of Science ®Google Scholar
• Kim DW, Kim JH, Park M, et al. Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials 2011;32:2593–604
   PubMed Web of Science ®Google Scholar
• Yu B, Mao Y, Bai LY, et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 2013;121:136–47
   PubMed Web of Science ®Google Scholar
• Dritschilo A, Huang CH, Rudin CM, et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006;12:1251–9
   PubMed Web of Science ®Google Scholar
• Rudin CM, Marshall JL, Huang CH, et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 2004;10:7244–51
   PubMed Web of Science ®Google Scholar
• Agrawal DK, Edwan J, Kandimalla ER, et al. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol 2004;4:127–38
   PubMed Web of Science ®Google Scholar
• Kandimalla ER, Bhagat L, Li Y, et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2’-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A 2005;102:6925–30
   PubMed Web of Science ®Google Scholar
• Kandimalla ER, Bhagat L, Wang D, et al. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003;31:2393–400
   PubMed Web of Science ®Google Scholar
• Wang D, Li Y, Yu D, et al. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 2004;24:901–8
   PubMed Web of Science ®Google Scholar
• Wilson JT, Keller S, Manganiello MJ, et al. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 2013;7:3912–25
   PubMed Web of Science ®Google Scholar
• Chen N, Wei M, Sun Y, et al. Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity. Small 2014;10:368–75
   PubMed Web of Science ®Google Scholar
• Burel SA, Han SR, Lee HS, et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther 2013;23:213–27
   PubMed Web of Science ®Google Scholar
• Burel SA, Machemer T, Ragone FL, et al. Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther 2012;342:150–62
   PubMed Web of Science ®Google Scholar
• Bourquin C, Anz D, Zwiorek K, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008;181:2990–8
   PubMed Web of Science ®Google Scholar
• Bourquin C, Wurzenberger C, Heidegger S, et al. Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J Immunother 2010;33:935–44
   PubMed Web of Science ®Google Scholar
• Park YM, Lee SJ, Kim YS, et al. Nanoparticle-Based Vaccine Delivery for Cancer Immunotherapy. Immune Netw 2013;13:177–83
   PubMedGoogle Scholar
• Silva JM, Videira M, Gaspar R, et al. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013;168:179–99
   PubMed Web of Science ®Google Scholar
• DNAi. Available from: http://www.pronai.com/pipeline/index.htm [Last accessed on 15 April 2015]
   Google Scholar
• Tolcher AW, Rodrigueza WV, Rasco DW, et al. A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:363–71
   PubMed Web of Science ®Google Scholar
• Harb W, Lakhani N, Logsdon A, et al. The BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 is active in patients with relapsed or refractory non-Hodgkin’s lymphoma. American Society of Hematology Annual Meeting; New Orleans, LA: 2013. p. 1–4
   Google Scholar
• Yehl K, Joshi JP, Greene BL, et al. Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation. ACS Nano 2012;6:9150–7
   PubMed Web of Science ®Google Scholar
• Clinical trials of Hgd40. Available from: http://clinicaltrials.gov/ct2/show/NCT02079688?term=DNAzyme&rank=5 [Last accessed 15 April 2015]
   Google Scholar
• Cho EA, Moloney FJ, Cai H, et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet 2013;381:1835–43
   PubMed Web of Science ®Google Scholar
• McNeer NA, Schleifman EB, Cuthbert A, et al. Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Ther 2013;20:658–69
   PubMed Web of Science ®Google Scholar
• Jakobsen U, Vogel S. Assembly of liposomes controlled by triple helix formation. Bioconjug Chem 2013;24:1485–95
   PubMed Web of Science ®Google Scholar
• Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res 2004;32:2102–12
   PubMed Web of Science ®Google Scholar
• Kundu AK, Chandra PK, Hazari S, et al. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm 2012;80:257–67
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819–29
   PubMed Web of Science ®Google Scholar
• Agrawal A, Min DH, Singh N, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009;3:2495–504
   PubMed Web of Science ®Google Scholar
• Zhou J, Wu J, Hafdi N, et al. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 2006;2362–4
   PubMed Web of Science ®Google Scholar
• Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659–68
   PubMed Web of Science ®Google Scholar
• Kang JH, Tachibana Y, Kamata W, et al. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier. Bioorg Med Chem 2010;18:3946–50
   PubMed Web of Science ®Google Scholar
• Hom C, Lu J, Liong M, et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 2010;6:1185–90
   PubMed Web of Science ®Google Scholar
• Li X, Chen Y, Wang M, et al. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013;34:1391–401
   PubMed Web of Science ®Google Scholar
• Li X, Xie QR, Zhang J, et al. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 2011;32:9546–56
   PubMed Web of Science ®Google Scholar
• Afonin KA, Grabow WW, Walker FM, et al. Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc 2011;6:2022–34
   PubMed Web of Science ®Google Scholar
• Afonin KA, Kireeva M, Grabow WW, et al. Co-transcriptional assembly of chemically modified RNA nanoparticles functionalized with siRNAs. Nano Lett 2012;12:5192–5
   PubMed Web of Science ®Google Scholar
• Afonin KA, Viard M, Martins AN, et al. Activation of different split functionalities on re-association of RNA-DNA hybrids. Nat Nanotechnol 2013;8:296–304
   PubMed Web of Science ®Google Scholar
• Afonin KA, Viard M, Kagiampakis I, et al. Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA-RNA Nanoparticles. ACS Nano 2015;9(1):251–9
   PubMed Web of Science ®Google Scholar
• Boraschi D, Costantino L, Italiani P. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine (Lond) 2012;7:121–31
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials: an introduction. In: Dobrovolskaia MA, McNeil SE, editors. Handbook of immunological properties of engineered nanomaterials. World Scientific publishing Co. Pte. Ltd; Singapore: 2013. p. 1–25
   Google Scholar
• Pantic I. Nanoparticles and modulation of immune responses. Sci Prog 2011;94:97–107
   PubMedGoogle Scholar
• Abrams MT, Koser ML, Seitzer J, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 2010;18:171–80
   PubMed Web of Science ®Google Scholar
• Kim JY, Choung S, Lee EJ, et al. Immune activation by siRNA/liposome complexes in mice is sequence- independent: lack of a role for Toll-like receptor 3 signaling. Mol Cells 2007;24:247–54
   PubMed Web of Science ®Google Scholar
• Li S, Wu SP, Whitmore M, et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 1999;276:L796–804
   PubMed Web of Science ®Google Scholar
• Vasievich EA, Chen W, Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother 2011;60:629–38
   PubMed Web of Science ®Google Scholar
• Sakurai H, Kawabata K, Sakurai F, et al. Innate immune response induced by gene delivery vectors. Int J Pharm 2008;354:9–15
   PubMed Web of Science ®Google Scholar
• Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 2012;109:2920–31
   PubMed Web of Science ®Google Scholar
• Wu J, Song C, Jiang C, et al. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. Mol Pharm 2013;10:3555–63
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Bambury RM, Van Allen EM, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 2014;32:178–87
   PubMed Web of Science ®Google Scholar
• Bates PJ, Malik MT, Kang KA. inventors; Anti-nucleolin agent conjugated nanoparticles. 2012. Application Number PCT/us2012/040577
   Google Scholar
• Ai J, Xu Y, Lou B, et al. Multifunctional AS1411-functionalized fluorescent gold nanoparticles for targeted cancer cell imaging and efficient photodynamic therapy. Talanta 2014;118:54–60
   PubMed Web of Science ®Google Scholar
• Dam DH, Culver KS, Odom TW. Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. Mol Pharm 2014;11:580–7
   PubMedGoogle Scholar
• Dam DH, Lee RC, Odom TW. Improved in vitro efficacy of gold nanoconstructs by increased loading of G-quadruplex aptamer. Nano Lett 2014;14:2843–8
   PubMed Web of Science ®Google Scholar
• Latorre A, Posch C, Garcimartin Y, et al. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale 2014;6:7436–42
   PubMed Web of Science ®Google Scholar
• Lale SV, Aravind A, Kumar DS, et al. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy. Biomacromolecules 2014;15:1737–52
   PubMed Web of Science ®Google Scholar
• Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 2014;15:1955–69
   PubMed Web of Science ®Google Scholar
• Zhang H, Hou L, Jiao X, et al. In vitro and in vivo evaluation of antitumor drug -loaded aptamer targeted single-walled carbon nanotubes system. Curr Pharm Biotechnol 2014;14(13):1105–17
   PubMed Web of Science ®Google Scholar
• Park W, Yang HN, Ling D, et al. Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking. Biomaterials 2014;35:7239–47
   PubMed Web of Science ®Google Scholar
• Alvarez RD, Sill MW, Davidson SA, et al. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2014;133:433–8
   PubMed Web of Science ®Google Scholar
• Anwer K, Kelly FJ, Chu C, et al. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2013;131:169–73
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release 2013;172:456–66
   PubMed Web of Science ®Google Scholar
• Szebeni J, Bedocs P, Rozsnyay Z, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012;8:176–84
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020–30
   PubMed Web of Science ®Google Scholar
• Tsai CY, Lu SL, Hu CW, et al. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 2012;188:68–76
   PubMed Web of Science ®Google Scholar
• Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004;11:169–83
   PubMed Web of Science ®Google Scholar
• Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 2012;22:177–92
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Patri AK, Potter TM, et al. Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) 2012;7:245–56
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Patri AK, Simak J, et al. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm 2012;9:382–93
   PubMed Web of Science ®Google Scholar
• Greish K, Thiagarajan G, Herd H, et al. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 2012;6:713–23
   PubMed Web of Science ®Google Scholar
• Ilinskaya AN, Man S, Patri AK, et al. Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) 2013
   Web of Science ®Google Scholar
• Jones CF, Campbell RA, Brooks AE, et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano 2012;6:9900–10
   PubMed Web of Science ®Google Scholar
• Jones CF, Campbell RA, Franks Z, et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharm 2012;9:1599–611
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Greish K, Ghandehari H. Charge affects the oral toxicity of poly(amidoamine) dendrimers. Eur J Pharm Biopharm 2013;84:330–4
   PubMed Web of Science ®Google Scholar
• Alaaeldin E, Abu Lila AS, Moriyoshi N, et al. The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex. Pharm Res 2013;30:2344–54
   PubMed Web of Science ®Google Scholar
• Ichihara M, Moriyoshi N, Lila AS, et al. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery. Methods Mol Biol 2013;948:35–47
   PubMedGoogle Scholar
• Tagami T, Uehara Y, Moriyoshi N, et al. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 2011;151:149–54
   PubMed Web of Science ®Google Scholar
• Crist RM, Grossman JH, Patri AK, et al. Common pitfalls in nanotechnology: lessons learned from NCI’s Nanotechnology Characterization Laboratory. Integr Biol (Camb) 2013;5:66–73
   PubMed Web of Science ®Google Scholar
• Grijalvo S, Avino A, Eritja R. Oligonucleotide delivery: a patent review (2010 - 2013). Expert Opin Ther Pat 2014;24(7):801–19
   PubMed Web of Science ®Google Scholar
• Henry SP, Monteith D, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997;12:395–408
   PubMedGoogle Scholar
• Tao W, Mao X, Davide JP, et al. Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol Ther 2011;19:567–75
   PubMed Web of Science ®Google Scholar
• Gottlieb P, Utz PJ, Robinson W. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clin Immunol 2013;149:297–306
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Saltzman WM, Slack FJ. Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem 2013;20:3582–93
   PubMed Web of Science ®Google Scholar
• Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014;32:461–88
   PubMed Web of Science ®Google Scholar